Cell ther­a­py biotech shifts fo­cus to UK, makes deep cuts to US head­count

It’s been less than two months since In­stil Bio re­vealed it would cut 60% of its US-based staff as the biotech scrapped its lead cell ther­a­py to fo­cus on next-gen ef­forts — but ex­ecs are al­ready go­ing for the next round of lay­offs.

In an ex­ten­sion of its work­force re­duc­tion, In­stil Bio is shrink­ing its US-based team to around 15 em­ploy­ees who will lead glob­al busi­ness op­er­a­tions. It marks a stark move for a com­pa­ny that’s head­quar­tered in Dal­las and pre­vi­ous­ly re­port­ed leas­ing of­fices in Greater Los An­ge­les as well as oth­er parts of the US, and that count­ed more than 450 em­ploy­ees around the world just over a year ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA